Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.84 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.84 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.83 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.83 |
| ▸ | NPY1R | P25929 | 1/20 | 0.83 |
| ▸ | NPY2R | P49146 | 1/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprolol SCHEMBL23668766 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL2406939 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| (S)-Metoprolol SCHEMBL379724 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL14744146 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL40917 | 1.00 | ADRB1 (0.84) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| (S)-Metoprolol SCHEMBL3123844 | 0.93 | ADRB2 (0.88) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL3123840 | 0.93 | ADRB2 (0.88) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL1561123 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| (R)-Metoprolol SCHEMBL40918 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 | |
| Metoprolol SCHEMBL4093 | 0.92 | ADRB1 (1.00) | ADRB1ADRB2ADRA1ACYP2D6NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5766 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260047897-A1 | TECHNICAL AND THEORETICAL SPECIFICATIONS FOR SMALL-SCALE MACHINES AND MICRO-ROBOTS FOR DESTROYING ANY HARMFUL MATTER INSIDE A LIVING ORGANISM USING A SUPERCRITICAL FLUID | HOFFMAN JASON (US) | 2026-02-19 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| WO-2025245481-A1 | METHODS AND MATERIALS FOR TREATING CARDIAC CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| EP-4615449-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | Weinberg, Assa (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | claimed |
| US-20250262195-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2025-08-21 | — | — | US | claimed |
| EP-4598526-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | Weinberg, Assa (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250228831-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2025-07-17 | — | — | US | claimed |
| US-20250223370-A1 | METHODS OF TREATING DISORDERS USING ANTI-NATRIURETIC PEPTIDE RECEPTOR 1 (NPR1) ANTIBODIES | NOVARTIS AG (CH) | 2025-07-10 | — | — | US | claimed |
| US-5001161-A | Pharmaceutical composition comprising metroprolol succinate | AKTIEBOLAGET HASSLE (SE) | 1991-03-19 | — | — | US | claimed |
| US-4942040-A | CONTROLLED AND EXTENDED RELEASE AGENTS FOR DELIVERY OF DRUGS OF DIHYDROPYRIDINES OR ADRENORECEPTOR ANTAGONIST SUCH AS METOPROLOL | AKTIEBOLAGET HASSLE (SE) | 1990-07-17 | — | — | US | claimed |
| CN-1032490-A | New pharmaceutical formulation and preparation method thereof | HAESSLE AB (SE) | 1989-04-26 | — | — | CN | claimed |
| EP-0311582-A1 | Pharmaceutical preparation with extended release of a dihydropyridine and a beta-adrenoreceptor antagonist and a process for the preparation thereof | Aktiebolaget Hässle (SE) | 1989-04-12 | — | — | EP | claimed |
| EP-0293347-A1 | Metoprolol succinate and pharmaceutical composition containing it | Aktiebolaget Hässle (SE) | 1988-11-30 | — | — | EP | claimed |
| US-4780318-A | DIFFERENT SOLUBILITIES AT DIFFERENT PHS | LEJUS MEDICAL AKTIEBOLAG (SE) | 1988-10-25 | — | — | US | claimed |
| CN-87101837-A | The method and apparatus of granulating and one-tenth granule product thereof | — | 1987-12-02 | — | — | CN | claimed |
| WO-1987005561-A1 | METHOD AND APPARATUS FOR GRANULATION AND GRANULATED PRODUCT | WASHINGTON UNIVERSITY TECHNOLOGY ASSOCIATES, INC. (US) | 1987-09-24 | — | — | WO | claimed |
| EP-0237345-A2 | Method and apparatus for granulation and granulated product | WASHINGTON UNIVERSITY TECHNOLOGY ASSOCIATES, INC. (US) | 1987-09-16 | — | — | EP | claimed |
| EP-0148811-A1 | Pharmaceutical composition | LEJUS MEDICAL AKTIEBOLAG (SE) | 1985-07-17 | — | — | EP | claimed |